Clinical Trials Logo

Filter by:
NCT ID: NCT01429064 Completed - Prostate Cancer Clinical Trials

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.

NCT ID: NCT01424670 Completed - Clinical trials for Multidrug-resistant Tuberculosis

Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis

Start date: September 2, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to determine whether delamanid is effective in the treatment of multidrug-resistant tuberculosis (MDR TB) in combination with other MDR TB medications during 6 months of treatment.

NCT ID: NCT01424137 Completed - Asthma Clinical Trials

Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)

SALIF
Start date: September 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to characterise inspiratory flow parameters across 2 Easyhaler® (EH) inhaler versions and Diskus® inhaler in patients with asthma (including children, adults, and the elderly) and in patients with chronic obstructive pulmonary disease (COPD).

NCT ID: NCT01422876 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Start date: August 2011
Phase: Phase 3
Study type: Interventional

This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.

NCT ID: NCT01408576 Completed - Clinical trials for Systemic Lupus Erythematosus

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

EMBODY4
Start date: July 2011
Phase: Phase 3
Study type: Interventional

The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)

NCT ID: NCT01374425 Completed - Colorectal Cancer Clinical Trials

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer

Start date: August 2011
Phase: Phase 2
Study type: Interventional

This will be a randomized, open-label, multicenter, phase II study. The study population will consist of participants with first-line metastatic colorectal cancer.

NCT ID: NCT01370005 Completed - Hypertension Clinical Trials

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Start date: June 2011
Phase: Phase 3
Study type: Interventional

This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2 diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of both glucose and blood pressure lowering effects of BI 10773 in hypertensive patients with type 2 diabetes could provide clinically highly relevant, new information for the use of BI 10773

NCT ID: NCT01369511 Completed - Muscular Atrophy Clinical Trials

A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement

Start date: July 2011
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older participants undergoing elective total hip arthroplasty (eTHA).

NCT ID: NCT01369056 Completed - Clinical trials for Medication Adherence

HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence

Start date: July 2010
Phase: N/A
Study type: Interventional

The general objective of this study is to evaluate HAART adherence in Estonia and the factors affecting adherence; and the impact of an individual adherence enhancement counselling and treatment monitoring model (Advanced Adherence, AdvAdh), compared to the regular counselling received by HAART patients.

NCT ID: NCT01366521 Completed - Asthma Clinical Trials

Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils

Start date: February 2011
Phase: Phase 2
Study type: Interventional

A multi-center, randomized, open-label, parallel-group, repeat dose study in asthma patients with elevated eosinophils. Eligible subjects will receive 3 doses (28 days apart) of mepolizumab given intravenous (IV) or subcutaneously (SC). Blood samples for safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity analysis, as well as safety/tolerability assessments will be collected throughout the study